Tuesday, April 7, 2020

Ixekizumab, Brodalumab Exhibit Greater Cumulative Clinical Benefit for Patients With Psoriasis, Study Shows – AJMC.com Managed Markets Network

Compared with other biologics approved for psoriasis treatment, excluding recently approved biologics, ixekizumab and brodalumab were shown to have greater cumulative clinical benefit for patients with psoriasis, according to study findings.

Related Articles

Compared with other biologics approved for psoriasis treatment, excluding recently approved biologics, ixekizumab and brodalumab were shown to have greater cumulative clinical benefit for patients with psoriasis, according to study findings published in the Journal of the American Academy of Dermatology.

Study authors highlight that cumulative clinical improvement and speed of improvement are vital measurements of treatment efficacy in patients with psoriasis. “Although cumulative life course impairment is a theoretical construct referring to the burden of disease over a long period of time, evaluating the cumulative clinical benefit, even over the first 12 to 16 weeks of treatment, can improve understanding of the impact of treatment on the patient,” said the study authors.

ADVERTISEMENT

To compare the cumulative clinical improvement and speed of improvement of biologics in the treatment of moderate to severe psoriasis, researchers conducted a systematic literature review measuring the cumulative benefits of biologics over 12 to 16 weeks. Eligible analyses included phase 3 trial data t Read More

Leave a Replay